Erratum to: p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways (Hepatology, (2011), 53, 1, (181-192), 10.1002/hep.24015);p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways

Hepatology

Volumn 53, Issue 1, 2011, Pages 181-192

  Fu, Jing ^a   Chen, Yao ^a   Cao, Jie ^a   Luo, Tao ^a   Qian, You Wen ^a   Yang, Wen ^a   Ren, Yi Bin ^a   Su, Bo ^a   Cao, Guang Wen ^b   Yang, Yuan ^c   Yan, Yi Qun ^c   Shen, Feng ^c   Wu, Meng Chao ^c   Feng, Gen Sheng ^a,d   Wang, Hong Yang ^a,e  

^a Eastern Hepatobiliary Surgery Institute/Hospital   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P28; REGULATOR PROTEIN; TWIST1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VIMENTIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEASOME; PSMD10 PROTEIN, HUMAN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE LEVEL; TUMOR VOLUME; BIOSYNTHESIS; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TWIST TRANSCRIPTION FACTOR;

EID: 78751544628     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.32762     Document Type: Erratum

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, et al. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-1134.
3. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538.
4. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 962-971.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547.
6. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006; 243: 229-235.
7. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. HEPATOLOGY 2008; 48: 2047-2063.
8. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000; 6: 96-99.
9. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002; 8: 638-643.
10. Iwai A, Marusawa H, Kiuchi T, Higashitsuji H, Tanaka K, Fujita J, et al. Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation. J Gastroenterol 2003; 38: 751-758.
11. GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-2041.
12. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005; 8: 75-87.
13. GANK knockdown-derived reactive oxygen species induces apoptosis through mitochondrial dysfunction mediated by p38 in HepG2 cells. Int J Oncol 2008; 33: 743-750.
14. GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity. Cell Res 2009; 19: 1243-1257.
15. Higashitsuji H, Higashitsuji H, Liu Y, Masuda T, Fujita T, Abdel-Aziz HI, et al. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem Biophys Res Commun 2007; 363: 879-884.
16. Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong LW, et al. Oncoprotein p28 GANK binds to RelA and retains NF-kappaB in the cytoplasm through nuclear export. Cell Res 2007; 17: 1020-1029.
17. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187-196.
18. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004; 130: 460-468.
19. Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O, et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res 2002; 24: 50.
20. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8: S62-S67.
21. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A 1997; 94: 4273-4278.
22. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
23. Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, et al. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J Clin Invest 2010; 120: 2829-2841.
24. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007; 245: 51-58.
25. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. HEPATOLOGY 2003; 37: 520-527.
26. Umemura A, Itoh Y, Itoh K, Yamaguchi K, Nakajima T, Higashitsuji H, et al. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. HEPATOLOGY 2008; 47: 493-502.
27. Ortiz CM, Ito T, Tanaka E, Tsunoda S, Nagayama S, Sakai Y, et al. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int J Cancer 2008; 122: 325-332.
28. Tang S, Yang G, Meng Y, Du R, Li X, Fan R, et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther 2010; 9: 88-95.
29. Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 2005; 11: 1705-1708.
30. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997; 94: 8104-8109.
31. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
32. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005; 24: 7443-7454.
33. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol 2009; 218: 451-454.
34. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81: 727-736.
35. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, et al. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62: 2971-2975.
36. Saeki Y, Toh EA, Kudo T, Kawamura H, Tanaka K. Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle. Cell 2009; 137: 900-913.